The Institute for Advanced Cellular Therapies (I-ACT)

I-ACT assists Tel Aviv Sourasky Medical Center academy researchers, doctors and industry collaborators developing their novel cell-based therapies into life-saving products administrated to patients enrolled in clinical research trials. I-ACT projects includes GMP manufacturing for clinical research studies designed to evaluate the safety and efficacy of these novel treatments.
All cell-manufacturing procedures are performed in environmentally controlled conditions according to current Good Manufacturing Practices for cell and tissue processing I-ACT projects include preparation of immune cell populations for adoptive cellular therapy, processing hematopoietic stem cells for allogeneic transplantation, generation of tumor vaccines and innovative gene therapy.
I-ACT is preparing for the first CAR-T product administration for Multiple Myeloma, planned to Q1 of 2021. The CAR-T product was developed by Ichilov’s researcher Prof. Zelig Eshhar, a pioneer of the CAR-T cell approach and its application for cancer therapy.
Recently, the development of a cell based therapy for companionate use involving manufacture of stem cells for the treatment of rare inherited skin disorder disease was achieved in collaboration with University of Minnesota.